About Dr. Suresh Kumar. B

• Dr. Suresh Kumar B is a passionate and accomplished Medical Oncologist with more than 11 years of medical experience.
• With a strong academic foundation and global training exposure, he is widely recognized for his expertise in precision and molecular oncology, targeted therapy, immunotherapy, bone marrow transplantation, and clinical trials.
• He is highly skilled in chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and bone marrow/stem cell transplantation, with a patient-centric approach that balances cure, disease control, and quality of life.
• He has successfully managed a wide spectrum of cancers, including head and neck, breast, thoracic, gastrointestinal, gynecological, and urological malignancies, as well as hematologic cancers requiring advanced treatments.
• He completed his MBBS from The Tamil Nadu Dr. M.G.R. Medical University in 2014, followed by MD in Internal Medicine from Madurai Medical College in 2017.
• He then pursued his DM in Medical Oncology from Tata Memorial Hospital, Mumbai, in 2020, where he gained advanced exposure to complex oncological cases and cutting-edge therapies.
• Dr. Suresh has also completed prestigious international certifications, including MRCP (UK) in Medical Oncology,  European Certified Medical Oncologist (ECMO), OCTT & ACORD (Australia) in Oncology Training and Protocol Development, and CCEPC in Palliative Care.
• Dr. Suresh Kumar has been recognized for his outstanding academic and clinical achievements, winning awards such as the Best Outgoing Student of MBBS (2014, Chengalpattu Medical College) and the Dr. Muthusethupathy Gold Medal in MD (Medicine) from Madras Medical College.
• He also secured multiple distinctions across MBBS and MD, reflecting his consistent academic excellence.
• As a dedicated researcher and academician, Dr. Suresh has published more than 30 papers in reputed national and international journals.
• His notable research includes studies on sarcomatoid carcinoma of the lung, safety and efficacy of generic pomalidomide, and a Phase II clinical trial on the role of maintenance lenalidomide in primary CNS lymphoma.
• He has also actively contributed to the development of oncology protocols and clinical trials at both national and international levels.
• He is an active member of leading professional bodies, including the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Indian Society of Oncology (ISO), Indian Society of Medical and Paediatric Oncology (ISMPO), and the Tamil Nadu Medical and Paediatric Oncology Society (TAMPOS).